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This systematic review and meta-analysis evaluated anti–programmed cell death (PD)-1 immunotherapy
(nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy
or other conventional drugs in the treatment of malignant tumors. We searched the following databases, PubMed,
Medline, Embase, Cochrane, Wangfang Data, Weipu, and China National Knowledge Infrastructure, and the
reference lists of the selected articles for randomized controlled trials (RCTs) of anti–PD-1 therapies in humans.
The outcome measures were overall survival, treatment response, and adverse events. Only four randomized
controlled trials met our inclusion criteria. Three of these evaluated responses to nivolumab, whereas one tested
pembrolizumab. The result of our analysis suggested that nivolumab may improve the overall response rate in
treating melanoma relative to chemotherapy and has few associated adverse events. Similarly, in metastatic
melanoma patients, nivolumab had a significant advantage over dacarbazine in terms of 1-year survival,
progression-free survival, and objective response rate. Regarding dose levels of nivolumab for patients with
metastatic renal cell carcinoma, the outcomes in response to 2 and 10 mg/kg were similar, but both had significant
advantages over 0.3 mg/kg. In addition, pembrolizumab showed similar outcomes in response to 2- and 10-mg/kg
treatment. Anti–PD-1 immunotherapy appears to be safe and effective for patients with melanoma or metastatic
renal cell carcinoma. Our meta-analysis is limited, but additional clinical trials are warranted to verify this
preliminary evidence of positive outcomes and before anti–PD-1 therapy can be recommended for routine
clinical use.
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Tumor malignancy remains the leading cause of death worldwide.
Based on the World Cancer Report of 2014 published by the World
Health Organization [1], in 2012, there were approximately 14 million
new cases and 8.2 million cancer-related deaths. Moreover, the burden
of cancer was predicted to increase by 70% over the next 2 decades [1].
Annual cancer cases were expected to rise from 14million in 2012 to 22
million within the next 2 decades.
Most patients with malignant disease that is advanced cannot be
cured by standard cancer therapies such as surgery, radiation, or
chemotherapy, and therefore additional options with few adverse
effects are being investigated. Cancer cells often acquire unlimited
Figure 1. Flowchart representing thesystematic identificationofstudies.
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characteristics include resisting cell death, sustained angiogenesis,
metastasis, avoiding immune detection, deregulating cellular ener-
getics, genome instability, and acquiring genetic mutations. Scientists
have focused on the signaling pathways that directly or indirectly
underlie and regulate these characteristics. Successful treatment of
cancers by targeting specific signaling pathways has been limited by
factors such as drug resistance and tumor reoccurrence.
Recently, the focus of research has shifted toward the immune system,
which has important roles in both tumor progression and its elimination
[2]. Consequently, immunotherapy has become a therapeutic option in
many cancer treatment regimens [3] that promises to increase clinical
efficacy for these patients [4]. Among the many immune targets,
programmed cell death-1 (PD-1) has shown promising results in the
treatment of melanoma and some other malignant tumors.
The PD-1 immunoinhibitory receptor is a type-1 transmembrane
protein that belongs to the cluster of differentiation 28 (CD28) familyand is usually expressed by activated immune cells like CD4+ and
CD8+ T cells. It mediates the immune response through
immunosuppression. In the context of tumors, it constitutes an
adaptive immune response, whereby dendritic cells detect the antigen
on tumor cells and eventually present the tumor antigen to T and B
cells. Subsequently, the T lymphocytes are activated when the T cell
receptor binds to the tumor antigen along with MHC proteins and
other co-stimulatory/inhibitory molecules and undergoes clonal
expansion. These T lymphocytes then migrate to the tumor sites
and generate a tumor suppressive response. Therefore, these
co-stimulatory and co-inhibitory molecules act as checkpoints to
ensure the appropriate response against foreign tumor antigens [5].
The PD-1 receptor has two ligands: PD-L1 and PD-L2. In the
tumor microenvironment, when PD-L1 that is expressed on tumor
cells binds to PD-1 on T cells, this results in recruitment of SHP-2
phosphatase and inactivation of the P13K pathway. In addition,
production and secretion of cytotoxic mediators are inhibited, and
thus finally, the T cell effector response that is required for killing
tumor cells is attenuated. Blocking this pathway was found to
enhance the antitumor immune response in cancer [6].
Anti–PD-1 antibodies can block the PD-1 pathway and prevent
suppression of the antitumor response [7–9]. The most common
antibodies presently used to block PD-1 are nivolumab and
pembrolizumab. Recently, the focus of anti–PD-1 therapy has been
in melanoma, but its therapeutic efficacy has also been tried in other
cancers such as renal cell carcinomas.
Although research into anti–PD-1 therapy is in the early stages and
few clinical trials have been undertaken, we have conducted a systematic
evaluation of this therapy to gauge its overall effectiveness. We also seek
to identify any additional parameters that may be included in future
clinical trials. Therefore, the present study is a systematic review and
meta-analysis undertaken to evaluate the positive benefit and effective
dose of anti–PD-1 therapy for the treatment of malignant tumors.
Specifically, we investigated the overall survival (OS) and effective rates,
effective dose, associated adverse events, and cancer recurrence rates.
Material and Methods
Identification of Studies
We searched the following databases electronically for all the anti–
PD-1 therapy-related studies, published or unpublished, ongoing or
pending, from January 1980 to December 2014: the Cochrane central
register of controlled trials in the Cochrane library, PubMed, Medline,
Embase, Ovid, National Institutes of Health, Chinese Biomedical
Literature Database, China National Knowledge Infrastructure,
Chinese Medical Current Contents, Wangfang Data, and Weipu. In
addition, to identify ongoing studies, we searched the following clinical
trial registries: International Standard Randomized Controlled Trial
Number, ClinicalTrials.gov, Chinese Clinical Trial Register
(www.chictr.org), WHO International Clinical Trial Registration
Platform search portal (www.who.int/trialsearch), and Australian
New Zealand Clinical Trials Registry (www.anzctr.org.au/). Moreover,
we found information concerning ongoing studies through two annual
meetings of the European Society of Medical Oncology.
Study Selection Criteria
Studies selected for the meta-analysis were all randomized
controlled trials (RCTs) involving patients with confirmed malignant
tumors, regardless of origin, tumor stage, age, or gender. All the
Figure 2. Assessment of risk bias.
Figure 3. Forest plot depicting the overall response rate of nivolumab compared with chemotherapy.
Figure 4. Forest plot depicting the comparison of adverse events associated with nivolumab and chemotherapy.
Figure 5. Forest plot depicting the 1-year OS rates of nivolumab and dacarbazine.
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treatment regimens. The compared, eligible control could be a
placebo or no intervention, conventional therapies (such as surgery,
chemotherapy, or radiotherapy), or other complementary or
alternative medicine. In addition, the studies contained survival
rate data for 1, 2, 3, or 5 years. Finally, the studies contained
data for complete response, partial response, stable disease, and
progressive disease.The studies were excluded if they were 1) non-RCTs; 2) animal
studies or in vitro studies; 3) without any information about the dose
of PD-1 antibody or the method of treatment; or 4) not reporting
either of the outcomes mentioned above.
Data Collection and Analysis
Two authors were independently assigned to peruse the relevant
articles found from the search of the databases and other sources, and
Figure 7. Forest plot depicting the objective response rates associated with nivolumab and dacarbazine.
Figure 8. Forest plot depicting the comparison of adverse events associated with nivolumab and dacarbazine.
Figure 9. Forest plot depicting the overall response rate with different doses (2 and 10 mg/kg) of pembrolizumab.
Figure 6. Forest plot depicting the PFS rates associated with nivolumab and dacarbazine.
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read the title and abstract to screen out irrelevant trials or duplicate
studies. Next, they reviewed the full-text articles to extract the
relevant information based on the inclusion criteria. Cases of
conflicting opinion were resolved through consultation with the
third author and discussion.
A data collection form was used to summarize the characteristics
and information from each RCT. The data fell into the following
categories: General information included publishing status, language,
authors, title, and date of publication. Information concerning
methods consisted of end points, intervention model, masking, and
the primary purpose of the study. Participant data included the total
number and the number in each comparison group, baseline
characteristics, age, gender, inclusion and exclusion criteria, and the
study setting. Intervention data consisted of the drug preparation,dose, regimen, and follow-up schedule. Outcomes included primary,
secondary, and other outcomes and adverse events associated with
treatment. Finally, information gathered from each study included
the data analyzed and the statistical methods used for data analysis.
Assessment of Risk Bias
We assessed the risk of bias in the included studies using the criteria
outlined in the Cochrane Handbook for Systematic Reviews of
Interventions [10].
Data Synthesis
We performed the meta-analysis using Review Manager Version 5.2
software [10]. Summarymeasures of efficacy and response rate and relative
risk (RR) for dichotomous variables, with 95% confidence intervals (95%
CIs), were calculated using a fixed-effects inverse variance model.
Figure 10. Forest plot depicting the PFS rates associated with different doses (2 and 10 mg/kg) of pembrolizumab.
Figure 11. Forest plot depicting 1-year survival rates associated with different doses (2 and 10 mg/kg) of pembrolizumab.
Figure 12. Forest plot depicting overall response rates of different doses (0.3 and 2 mg/kg) of nivolumab.
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Based on the search criteria, we initially identified 3996 studies from
our database search (Figure 1). In addition, we found one other study
through an annual meeting of the European Society of Medical
Oncology. Among these, 3785 studies were excluded because they
did not meet our selection criteria. Of the remaining 212 studies, only
4 passed the inclusion criteria, and the rest were excluded because of
repetitive or insufficient information. After reading the full texts of
these four studies, we found that all of them met our inclusion criteria
and hence were included for further analysis.
All of the 4 included studies evaluated the effectiveness of anti–
PD-1 therapy, with data from a combined total of 1294 patients.
Among the four studies, three [11–13] contained data from
melanoma patients, and one study concerned metastatic renal cell
carcinoma [14].
We assessed the quality of each study (i.e., risk of bias)
independently based on the RCT quality evaluation standards of
the Cochrane review manual (Figure 2). Information regarding
random sequence generation, allocation concealment, blinding
method, incomplete outcome data, and selective reporting was
gathered from each study. If there was information for all the
parameters, then the study was assigned as low bias. If there was no
information at all, the study was described as high bias. The risk of
bias in studies with partial or unclear information was defined as
unclear. We could only obtain the information about the method of
allocation from all the studies, and they were found to be randomized.
Only one study had information regarding blinding [14].Comparison of Anti–PD-1 Interventions
Nivolumab cf. chemotherapy. Overall response rate. Among the
four RCTs, only one study [12] contained data for the overall
response rate after comparing nivolumab treatment relative to
chemotherapy. The data were reported as dichotomous. After
meta-analysis, it was represented as a forest plot (Figure 3). The
overall response rate was statistically significant (RR 2.98, 95% CI
1.66 to 5.43, P = .0003) in favor of nivolumab. It was suggested that
patients were more likely to respond to anti–PD-1 treatment and that
nivolumab can improve the overall response rate.
Adverse events. The same study byWeber et al. (2014) also provided
data comparing adverse events between nivolumab and chemotherapy
(Figure 4) [12]. The meta-analysis of drug-related adverse events showed
that nivolumab had fewer associated adverse events. The RR ratio was
0.29 (95% CI 0.18 to 0.48) and was highly significant (P b .000001).
Nivolumab cf. dacarbazine.One year-OS, progression-free survival
(PFS), and objective response rate. The study by Caroline et al.
[13] compared the effects of nivolumab and dacarbazine in the
treatment of metastatic melanoma patients without BRAF (B-Raf
proto-oncogene, serine/threonine kinase) mutation. The data
retrieved from this study were pooled and presented in forest plots
for 1-year OS, median PFS, and objective response rate (Figures 5–7).
The 1-year rate for OS with RR value of 1.74 (95% CI 1.45 to
2.09) suggested that nivolumab had a clear significant advantage over
dacarbazine (P b .00001; Figure 5). Similarly, the median PFS also
showed significant advantage for nivolumab with a mean difference
Figure 14. Forest plot depicting the OS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab.
Figure 15. Forest plot depicting the overall response rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
Figure 16. Forest plot depicting PFS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
Figure 13. Forest plot depicting the PFS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab.
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the data regarding the objective response rates to these two treatments
were analyzed and represented as a forest plot; this analysis also
highlighted the significant advantage of nivolumab over dacarbazine,
with RR ratio of 2.77 (95% CI 1.92 to 4.02, P b .00001, Figure 7).
Adverse events. The analysis of adverse events comparing nivolumab
with dacarbazine in melanoma patients suggested that nivolumab was
associatedwith slightly fewer adverse events than dacarbazine (Figure 8),
although the difference was not statistically significant. The observed
RR value was 0.98 (95% CI 0.88 to 1.10, P = .75).
Assessment of Effective Anti–PD-1 Doses
Pembrolizumab (2 mg cf. 10 mg). Overall response rate, PFS, and 1-
year survival rate. The study by Robert et al. [11] compared theefficacy and safety of pembrolizumab, an anti–PD-1 antibody,
in patients who had ipilimumab-refractory advanced melanoma.
The two different doses, 2 and 10 mg/kg, were administered every
3 weeks to these patients. The meta-analysis of this dichotomous
data revealed that the overall response rates from both these
concentrations were not significantly different, with an RR value of
0.99 (95% CI 0.60 to 1.63, P = .96, Figure 9). This suggested that
increasing the dose from 2 to 10 mg/kg did not enhance the overall
response rate.
Similarly, further analysis of PFS (MD 8.0, 95% CI −2.06 to
18.06, P = .12, Figure 10) and the 1-year survival rates (RR 0.91,
95% CI 0.71 to 1.16, P = .44, Figure 11) also revealed that there were
insignificant differences between the 2- and 10-mg/kg doses. The
10-mg/kg dose had no advantage in improving PFS or the 1-year
survival rate.
Figure 17. Forest plot depicting the OS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
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OS. Motzer et al. [14] conducted a comparison of different doses
of nivolumab in patients with metastatic renal cell carcinoma. Our
meta-analysis of the data was performed for patients who received
either 0.3 or 2 mg/kg of nivolumab (Figure 12). The overall response
rate was almost similar between these two doses (RR 0.90, 95% CI
0.44 to 1.83, P = .77). In contrast, the patients receiving 2 mg/kg had
significantly better PFS than did those administered 0.3 mg/kg
(MD −1.30, 95% CI −2.71 to 0.11, P = .07, Figure 13). Those in
the 2-mg/kg group also had significantly better OS (MD −7.30,
95% CI −13.20 to −1.40, P = .02, Figure 14). This suggests that
2-mg/kg nivolumab therapy was associated with longer PFS and
OS relative to that of 0.3 mg/kg, whereas the overall response
rates were similar.
Nivolumab (0.3 mg cf. 10 mg). Overall response rate, PFS, and
OS. Motzer et al. [14] compared the efficacies associated with
0.3- and 10-mg/kg doses of nivolumab in metastatic renal cell
carcinoma patients. Regarding the overall response rates, the 10-mg/kg
dose had no significant advantage over the 0.3-mg/kg dose (RR 0.98,
95% CI 0.47 to 2.04, P = .96, Figure 15). However, the higher dose
was associatedwith significantly better PFS andOS (Figures 16 and 17):
for PFS, theMDvalue was −1.50 (95%CI −3.08 to 0.08, P = .06), and
for OS, the MD value was −6.50 (95% CI −5.89 to 2.89, P = .17).
Therefore, the 10-mg/kg dose of nivolumab was associated with
significantly longer PFS and OS relative to the 0.3-mg/kg dose.
However, the overall response rate did not differ much between these
two doses.
Nivolumab (2 mg cf. 10 mg). Overall response rate, PFS, and
OS. We also performed a meta-analysis of the differences in
outcomes between the 2- and 10-mg/kg doses of nivolumab in
metastatic renal cell carcinoma patients [14]. With regard to overall
response rates, OS, and PFS, the two treatment groups were similar in
outcomes (Figures 18, 19, and 20, respectively); the RR value for
overall response rates was 1.09 (95% CI 0.53 to 2.25, P = .81), MD
value for OS was–0.80 (95% CI −9.94 to 11.54, P = .88), and MD
value for PFS was −0.20 (95% CI −2.00 to 1.60, P = .83).Figure 18. Forest plot depicting the overall response rates assDiscussion
Promising clinical data regarding antibodies that block PD-1 and
PD-L1 in different malignancies have recently begun to emerge.
Among cancer studies, the major focus of anti–PD-1 therapy has been
in melanoma, but preliminary reports have suggested positive
outcomes in other cancers as well. The initial evidence is that anti–
PD-1 antibodies display strong and significant antitumor activity by
targeting the PD-1/PD-L1 pathway in cancers such as melanoma and
lymphoma [15–17], leukemia [7,18], neuroblastoma [19], brain and
central nervous system cancers [20,21], retinoblastoma [22], Wilm’s
tumor [23], soft-tissue sarcoma [24], and osteosarcoma [25]. The
open-label, randomized, phase 3 study by Weber et al. [12] showed
that anti–PD-1 therapy was associated with a higher rate of objective
response than chemotherapy.
In the current study, we undertook a comprehensive systematic
review by meta-analysis of RCTs to assess the efficacy, safety, and
effective dose of anti–PD-1 therapy in tumor treatments. An effort
was made to pool the available data from individual trials and produce
an overall summary of OS, PFS, 1-year survival, adverse events, and
effective dose concentrations. Our first analysis comparing nivolumab
with chemotherapy in advanced melanoma patients revealed a
significantly higher overall response rate associated with nivolumab
compared with chemotherapy. In addition, nivolumab treatment
resulted in fewer adverse events. The analysis comparing nivolumab
with dacarbazine in metastatic melanoma patients again revealed that
nivolumab had a significant advantage with regard to 1-year survival,
PFS, and objective response rate. Nivolumab also had fewer
associated adverse events than dacarbazine, but the difference was
not significant. It can be deduced that analysis of more studies might
reveal a more significant advantage. We also compared different doses
of pembrolizumab or nivolumab. For pembrolizumab, all of the
effects analyzed at the tested doses (2 and 10 mg/kg) were statistically
similar. In contrast, for nivolumab, the analyses for 0.3, 2, and 10mg/kg
suggested that the 2 and 10 mg/kg resulted in significantly longer PFS
and OS relative to the 0.3-mg/kg treatment, whereas no differences
were found in overall response rates.ociated with different doses (2 and 10 mg/kg) of nivolumab.
Figure 19. Forest plot depicting the OS rates associated with different doses (2 and 10 mg/kg) of nivolumab.
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on a single RCT, and the sample size of each study was small. Both of
these limitations resulted in low statistical power in assessing the
overall efficacy of anti–PD-1 therapy. However, as anti–PD-1
immunotherapy is a relatively new approach in the treatment of
malignant tumors, there are little published data; most RCT studies
are currently still under way. Because of the limited number of studies
for each analysis, we could not confidently assess publication bias or
conduct a sensitivity analysis. Another limitation concerns the
effective dose concentrations of these treatments. Effective doses
have not been standardized, but we observed that, past a certain dose,
no further improvement was observed in patient outcomes.
Therefore, effective and minimum doses need to be determined so
that patients can achieve maximum therapeutic benefit with
minimum adverse effects.
Our analysis indicated that anti–PD-1 therapy is associated with
fewer adverse events than either chemotherapy or dacarbazine
treatments, which is in accord with previous reports. The most
common adverse events observed with anti–PD-1 therapy are fatigue,
pruritus, nausea, diarrhea, rash, vitiligo, constipation, asthenia, and
vomiting. Therefore, when standardizing an anti–PD-1 therapy
regimen for malignant tumors, additional combinations of drugs to
prevent or treat these adverse events should be considered.
Conclusions
In summary, our meta-analysis results suggest that anti–PD-1 therapy
is indeed a promising approach for the treatment of malignant
tumors, with significant associated improvements in PFS, OS, and
1-year survival rates relative to chemotherapy and other treatments,
and fewer adverse events. However, because our analyses were based
on a single RCT study with a small sample size, caution must be
considered. In addition, the outcomes in these studies were not
blinded. To improve the credibility of future anti PD-1 therapy
studies requires multicenter RCTs with large sample size, analysis of a
wide range of doses, and explicit blinding of the outcome assessors,
and finally, the cost-utility of the therapy should be addressed.Figure 20. Forest plot depicting the PFS rates associateReferences
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